Market openNon-fractional

Kura Oncology/KURA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Ticker

KURA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

142

Kura Oncology Metrics

BasicAdvanced
$1.7B
Market cap
-
P/E ratio
-$2.18
EPS
0.87
Beta
-
Dividend rate
$1.7B
0.87
16.669
16.47
3.09
3.36
-94.35%
-23.43%
-37.34%
3.39
3.39
-12.509
6.84%
7.91%

What the Analysts think about Kura Oncology

Analyst Ratings

Majority rating from 14 analysts.
Buy

Kura Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$50M
15.93%
Profit margin
0.00%
NaN%

Kura Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.34%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.53
-$0.50
-$0.55
-$0.59
-
Expected
-$0.55
-$0.55
-$0.55
-$0.55
-$0.63
Surprise
-3.62%
-9.00%
0.13%
7.34%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Kura Oncology stock?

Kura Oncology (KURA) has a market cap of $1.7B as of July 15, 2024.

What is the P/E ratio for Kura Oncology stock?

The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of July 15, 2024.

Does Kura Oncology stock pay dividends?

No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of July 15, 2024.

When is the next Kura Oncology dividend payment date?

Kura Oncology (KURA) stock does not pay dividends to its shareholders.

What is the beta indicator for Kura Oncology?

Kura Oncology (KURA) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Kura Oncology stock

Buy or sell Kura Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing